192 related articles for article (PubMed ID: 31019861)
1. Favorable Response of Metastatic Hepatocellular Carcinoma to Treatment with Trans-arterial Radioembolization Followed by Sorafenib and Nivolumab.
Adcock CS; Puneky LV; Campbell GS
Cureus; 2019 Feb; 11(2):e4083. PubMed ID: 31019861
[TBL] [Abstract][Full Text] [Related]
2. Locoregional and systemic therapy for hepatocellular carcinoma.
Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
[TBL] [Abstract][Full Text] [Related]
3. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Gramenzi A; Golfieri R; Mosconi C; Cappelli A; Granito A; Cucchetti A; Marinelli S; Pettinato C; Erroi V; Fiumana S; Bolondi L; Bernardi M; Trevisani F;
Liver Int; 2015 Mar; 35(3):1036-47. PubMed ID: 24750853
[TBL] [Abstract][Full Text] [Related]
4. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma.
Kallini JR; Gabr A; Salem R; Lewandowski RJ
Adv Ther; 2016 May; 33(5):699-714. PubMed ID: 27039186
[TBL] [Abstract][Full Text] [Related]
5. Intra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled Trial.
Chauhan N; Bukovcan J; Boucher E; Cosgrove D; Edeline J; Hamilton B; Kulik L; Master F; Salem R
JMIR Res Protoc; 2018 Aug; 7(8):e11234. PubMed ID: 30111528
[TBL] [Abstract][Full Text] [Related]
6. Y-90 Radioembolization Combined with a PD-1 Inhibitor for Advanced Hepatocellular Carcinoma.
Wehrenberg-Klee E; Goyal L; Dugan M; Zhu AX; Ganguli S
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1799-1802. PubMed ID: 29845347
[TBL] [Abstract][Full Text] [Related]
7. Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy.
Goh MJ; Kang W; Sinn DH; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
J Liver Cancer; 2020 Sep; 20(2):160-166. PubMed ID: 37384324
[TBL] [Abstract][Full Text] [Related]
8. Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments.
Cappelli A; Pettinato C; Golfieri R
J Hepatocell Carcinoma; 2014; 1():163-82. PubMed ID: 27508185
[TBL] [Abstract][Full Text] [Related]
9. Radioembolization for the treatment of hepatocellular carcinoma.
Kim HC
Clin Mol Hepatol; 2017 Jun; 23(2):109-114. PubMed ID: 28494530
[TBL] [Abstract][Full Text] [Related]
10. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality.
Kim DY; Han KH
Hepatol Int; 2016 Nov; 10(6):883-892. PubMed ID: 27126821
[TBL] [Abstract][Full Text] [Related]
11. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment strategies other than sorafenib for the patients with advanced hepatocellular carcinoma invading portal vein.
Yu SJ; Kim YJ
World J Hepatol; 2015 Jun; 7(11):1553-61. PubMed ID: 26085914
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
14. Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis.
Facciorusso A; Bargellini I; Cela M; Cincione I; Sacco R
Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32272656
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab for Advanced Hepatocellular Carcinoma with Multiple Lung Metastases after Sorafenib Failure.
Kim J; Chang JW; Park JY
J Liver Cancer; 2020 Mar; 20(1):72-77. PubMed ID: 37383058
[TBL] [Abstract][Full Text] [Related]
16. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis.
Rognoni C; Ciani O; Sommariva S; Bargellini I; Bhoori S; Cioni R; Facciorusso A; Golfieri R; Gramenzi A; Mazzaferro V; Mosconi C; Ponziani F; Sacco R; Trevisani F; Tarricone R
BMC Cancer; 2018 Jul; 18(1):715. PubMed ID: 29976149
[TBL] [Abstract][Full Text] [Related]
17. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Rognoni C; Ciani O; Sommariva S; Tarricone R
Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
Wang EA; Stein JP; Bellavia RJ; Broadwell SR
Int J Clin Pract; 2017 Nov; 71(11):. PubMed ID: 28758319
[TBL] [Abstract][Full Text] [Related]
19. Yttrium-90 microsphere radioembolization for hepatocellular carcinoma.
Edeline J; Gilabert M; Garin E; Boucher E; Raoul JL
Liver Cancer; 2015 Mar; 4(1):16-25. PubMed ID: 26020026
[TBL] [Abstract][Full Text] [Related]
20. Transarterial Radioembolization Versus Concurrent Chemoradiation Therapy for Locally Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Song JE; Jung KS; Kim DY; Song K; Won JY; Lee HW; Kim BK; Kim SU; Park JY; Ahn SH; Seong J; Han KH
Int J Radiat Oncol Biol Phys; 2017 Oct; 99(2):396-406. PubMed ID: 28871990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
